Liver transplantation for colorectal secondaries: on the way to validation.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
ppublish
Résumé
Liver transplantation for nonresectable colorectal liver metastases (CRLMs) is an emerging field within transplant oncology. This review summarizes recent developments within this field. More stringent selection criteria can yield 5-year survival rates that are similar to conventional indications for liver transplantation. Response to chemotherapy, low carcinoembryonic antigen levels, limited tumor volume and stable disease with observation time exceeding 12 months are fundamental requirements in this context. Radiomic analysis of pre transplant PET/computed tomography scans to determine metabolic tumor volume (MTV) in the liver seems particularly promising with regards to prediction of a favorable tumor biology. MTV values below 70 cm3 are associated with excellent long-term survival after transplantation, whereas the MTV threshold for liver resection seem far smaller. Recent studies put into question whether technical nonresectability per se is a valid inclusion criterion for liver transplantation. In patients with high hepatic tumor burden, but otherwise favorable prognostic features as assessed by the Oslo score, liver transplantation could possibly give a clinically relevant survival benefit compared with liver resection. Liver transplantation is feasible treatment option in highly selected patients with nonresectable CRLMs. Robust and stringent selection criteria should be applied according to international consensus guidelines.
Identifiants
pubmed: 36354259
doi: 10.1097/MOT.0000000000000977
pii: 00075200-202208000-00014
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-336Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359–E386.
Vuik FE, Nieuwenburg SA, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68:1820–1826.
Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 2012; 151:860–870.
Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4:283–301.
Kron P, Linecker M, Jones RP, et al. Ablation or resection for colorectal liver metastases? A systematic review of the literature. Front Oncol 2019; 9:1052.
Ciliberto D, Prati U, Roveda L, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep 2012; 27:1849–1856.
Schadde E, Ardiles V, Robles-Campos R, et al. Early survival and safety of ALPPS. Ann Surg 2014; 260:829–838.
Sandstrom P, Røsok BI, Sparrelid E, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a scandinavian multicenter randomized controlled trial (LIGRO trial). Ann Surg 2018; 267:833–840.
Lam VWT, Laurence JM, Johnston E, et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB 2013; 15:483–491.
Chebaro A, Buc E, Durin T, et al. Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy? Ann Surg 2021; 274:874–880.
Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg 2019; 3:50–56.
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38–47.
Jones RP, Hamann S, Malik HZ, et al. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 2014; 50:1590–1601.
Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955–1967). J Am Col Surg 2002; 195:587–610.
Mühlbacher F, Huk I, Steininger R, et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc 1991; 23 (1 Pt 2):1567–1568.
Hagness M, Foss A, Line P-D, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013; 257:800–806.
Bonney GK, Chew CA, Lodge P, et al. Liver transplantation for nonresectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021; 6:933–946.
Grut H, Revheim ME, Line P-D, Dueland S. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nucl Med Commun 2018; 39:1–627.
Bai B, Bading J, Conti PS. Tumor quantification in clinical positron emission tomography. Theranostics 2013; 3:787–801.
Grut H, Dueland S, Line P-D, Revheim ME. The prognostic value of (18)F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging 2017; 4: (Suppl 1): 283.
Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25:1995–2001.
Smedman TM, Line P-D, Hagness M, et al. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open 2020; 4:467–477.
Dueland S, Guren TK, Hagness M, et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg 2014; 261:956–960.
Dueland S, Hagness M, Line P-D, et al. Is liver transplantation an option in colorectal cancer patients with nonresectable liver metastases and progression on all lines of standard chemotherapy? Ann Surg Oncol 2014; 22:1–6.
Dueland S, Line PD, Hagness M, et al. Long-term quality of life after liver transplantation for nonresectable colorectal metastases confined to the liver. BJS Open 2018; 3:180–185.
Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res 2021; 27:4680–4684.
Dai Y, Zhao W, Yue L, et al. Perspectives on immunotherapy of metastatic colorectal cancer. Front Oncol 2021; 11:659964.
Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 2020; 25:505–514.
Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019; 7:106.
Dueland S, Grut H, Syversveen T, et al. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant 2019; 20:530–537.
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–318. discussion 318–321.
Dueland S, Syversveen T, Solheim JM, et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 2020; 271:212–218.
Hagness M, Foss A, Egge TS, Dueland S. Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg Oncol 2014; 21:1323–1329.
Line P-D, Ruffolo LI, Toso C, et al. Liver transplantation for colorectal liver metastases: what do we need to know? Int J Surg Lond Engl 2020; 82S:87–92.
Grut H, Solberg S, Seierstad T, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg 2018; 105:295–301.
Dueland S, Smedman TM, Røsok B, et al. Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases. Transplant Int 2021; 34:2205–2213.
Bowring MG, Massie AB, Schwarz KB, et al. Survival benefit of split liver transplantation for pediatric and adult candidates. Liver Transplant 2021.
Sneiders D, Dijk ARM, Polak WG, et al. Full-left-full-right split liver transplantation for adult recipients: a systematic review and meta-analysis. Transplant Int 2021; 34:2534–2546.
Broering DC, Wilms C, Lenk C, et al. Technical refinements and results in full-right full-left splitting of the deceased donor liver. Ann Surg 2005; 242:802–813.
Line P-D, Hagness M, Berstad AE, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann Surg 2015; 262:e5–e9.
Nadalin S, Königsrainer A, Capobianco I, et al. Auxiliary living donor liver transplantation combined with two-stage hepatectomy for unresectable colorectal liver metastases. Curr Opin Organ Transplant 2019; 24:651–658.
Nadalin S, Settmacher U, Rauchfuß F, et al. RAPID procedure for colorectal cancer liver metastasis. Int J Surg 2020; 82S:93–96.
Donadon M, Cescon M, Cucchetti A, et al. Parenchymal-sparing surgery for the surgical treatment of multiple colorectal liver metastases is a safer approach than major hepatectomy not impairing patients’ prognosis: a bi-institutional propensity score-matched analysis. Digest Surg 2017; 35:342–349.
Allard MA, Adam R, Giuliante F, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer 2017; 117:604–611.
Sasaki K, Margonis GA, Andreatos N, et al. The prognostic utility of the ‘Tumor Burden Score’ based on preoperative radiographic features of colorectal liver metastases. J Surg Oncol 2017; 116:515–523.
Sasaki K, Morioka D, Conci S, et al. The tumor burden score: a new ‘metro-ticket’ prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 2018; 267:132–141.
Tam HH, Cook GJ, Chau I, et al. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis. Clin Nucl Med 2015; 40:e259–e264.
Grut H, Stern NM, Dueland S, et al. Preoperative 18F-FDG PET/computed tomography predicts survival following resection for colorectal liver metastases. Nucl Med Commun 2020; 41:916–923.
Grut H, Line P-D, Labori KJ, et al. Survival after liver resection and liver transplantation for colorectal liver metastases: a comparative analysis stratified by metabolic tumor volume assessed by 18F-FDG PET/CT. HPB 2021.
Lanari J, Hagness M, Sartori A, et al. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transplant Int 2021; 34:1722–1732.
Benítez C, Londoño M-C, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58:1824–1835.
Lerut JP, Pinheiro RS, Lai Q, et al. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. Ann Surg 2014; 260:886–892.
Manzia T-M, Angelico R, Toti L, et al. Long-term survival and cost-effectiveness of immunosuppression withdrawal after liver transplantation. Liver Transplant 2018; 24:1199–1208.